



## INFORMATION FOR HEALTHCARE PROFESSIONALS

## RISK EVALUATION AND MITIGATION STRATEGY (REMS)

A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.

VIVITROL, when used as part of a comprehensive management program, is indicated for the following:

- Treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.
- Prevention of relapse to opioid dependence, following opioid detoxification.

Providers and patients should be aware of the following risks of VIVITROL:

- Risk of opioid overdose
- Severe injection site reactions
- Precipitation of opioid withdrawal during initiation and re-initiation of VIVITROL
- Hepatotoxicity
- Patients may not feel the therapeutic effects of opioid-containing medicines for pain, cough or cold, or diarrhea while taking VIVITROL.

## Materials for Healthcare Providers

[Dear Healthcare Provider Letter](#) ▶

[Patient Counseling Tool for Providers](#) ▶

[Important Injection Safety Information Poster](#) ▶

To order any of the healthcare provider materials, call:



**1-800-848-4876**

and press 1.

- Dear Healthcare Provider Letter
- Patient Counseling Tool for Providers
- Important Injection Safety Information Poster
- Patient Wallet Card
- Patient Safety Bracelet



[Privacy](#) | [Terms of Use](#)

Alkermes® and VIVITROL® are registered trademarks of Alkermes, Inc.  
For U.S. Audience Only. For information call 1-800-848-4876. Please see our online privacy policy for more information.  
Copyright ©2013 Alkermes, Inc. All rights reserved.

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JUDITH A RACOOSIN  
05/17/2016